Ruiz Ciancio Dario, Vargas Mauricio R, Thiel William H, Bruno Martin A, Giangrande Paloma H, Mestre María Belén
Biomedical Science Institute (ICBM), Catholic of Cuyo University, San Juan, CP 5400, Argentina.
Department of Internal Medicine, University of Iowa, Iowa City, IA 52246, USA.
Pharmaceuticals (Basel). 2018 Sep 11;11(3):86. doi: 10.3390/ph11030086.
Cancer is the second leading cause of death worldwide. Researchers have been working hard on investigating not only improved therapeutics but also on early detection methods, both critical to increasing treatment efficacy, and developing methods for disease prevention. The use of nucleic acids, or aptamers, has emerged as more specific and accurate cancer diagnostic and therapeutic tools. Aptamers are single-stranded DNA or RNA molecules that recognize specific targets based on unique three-dimensional conformations. Despite the fact aptamer development has been mainly restricted to laboratory settings, the unique attributes of these molecules suggest their high potential for clinical advances in cancer detection. Aptamers can be selected for a wide range of targets, and also linked with an extensive variety of diagnostic agents, via physical or chemical conjugation, to improve previously-established detection methods or to be used as novel biosensors for cancer diagnosis. Consequently, herein we review the principal considerations and recent updates in cancer detection and imaging through aptamer-based molecules.
癌症是全球第二大死因。研究人员一直在努力不仅研究改进的治疗方法,还研究早期检测方法,这两者对于提高治疗效果以及开发疾病预防方法都至关重要。核酸或适配体的使用已成为更具特异性和准确性的癌症诊断和治疗工具。适配体是基于独特的三维构象识别特定靶标的单链DNA或RNA分子。尽管适配体的开发主要局限于实验室环境,但这些分子的独特特性表明它们在癌症检测的临床进展方面具有很高的潜力。适配体可以针对广泛的靶标进行筛选,并且还可以通过物理或化学偶联与多种诊断试剂相连,以改进先前建立的检测方法或用作癌症诊断的新型生物传感器。因此,在此我们综述了基于适配体的分子在癌症检测和成像方面的主要考虑因素和最新进展。